Thursday Morning Pre-Market Insights: EXAS, AVEO, ONTY, DBVT

EXACT Sciences Corporation (NASDAQ:EXAS) shares increased 2.51% to $28.16 following an announcement that the company will be partnering with The University of Texas MD Anderson Cancer Center to develop screening and diagnostic tests for lung cancer. The two entities will work together to develop and commercialize blood-based screening for early detection of lung cancer. According to TipRanks, the average 12-month price target from top analysts rating the stock is $30.50, marking an 11% upside from where the stock is currently trading.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares increased 12.07% to $2.60 following news that the pharmaceutical company has received written support for the filing of a Marketing Authorization Application for tivozanib, a drug for renal cell carcinoma, in Europe. If the application is filed, it will be based on the existing data from the Phase 3 study.

Oncothyreon Inc (USA) (NASDAQ:ONTY) shares increased 3.68% to $4.23 in pre-market trading after the pharmaceutical company announced positive data on a lung cancer pipeline drug. Furthermore, ONTY presented at the American Association of Clinical Oncology conference in Chicago. The company presented updated data on ONT-380, a breast cancer therapy, confirming that it has a benign safety profile. Out of the three analysts polled by TipRanks, two have a Buy rating on the stock and one has a Hold.

DBV Technologies SA – ADR (NASDAQ:DBVT) shares rose 8.40% to $25.93 in pre-market trading following an announcement that the Pediatric Committee of the European Medicines Agency shared a positive opinion on Viaskin Peanut, an immunotherapy for peanut allergies. This makes it one step closer to being eligible to submit a Marketing Authorization Application in Europe.

Disclosure: To see more visit  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.